These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 12825462)

  • 1. The first structure of a microsomal P450--implications for drug discovery.
    Tennant M; McRee DE
    Curr Opin Drug Discov Devel; 2001 Sep; 4(5):671-7. PubMed ID: 12825462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of drug-like molecular properties: modeling cytochrome p450 interactions.
    Jalaie M; Arimoto R; Gifford E; Schefzick S; Waller CL
    Methods Mol Biol; 2004; 275():449-520. PubMed ID: 15141126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human P450s involved in drug metabolism and the use of structural modelling for understanding substrate selectivity and binding affinity.
    Lewis DF; Ito Y
    Xenobiotica; 2009 Aug; 39(8):625-35. PubMed ID: 19514836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microsomal cytochrome P450 2C5: comparison to microbial P450s and unique features.
    Williams PA; Cosme J; Sridhar V; Johnson EF; McRee DE
    J Inorg Biochem; 2000 Aug; 81(3):183-90. PubMed ID: 11051563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designing better drugs: predicting cytochrome P450 metabolism.
    de Groot MJ
    Drug Discov Today; 2006 Jul; 11(13-14):601-6. PubMed ID: 16793528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High confidence predictions of drug-drug interactions: predicting affinities for cytochrome P450 2C9 with multiple computational methods.
    Hudelson MG; Ketkar NS; Holder LB; Carlson TJ; Peng CC; Waldher BJ; Jones JP
    J Med Chem; 2008 Feb; 51(3):648-54. PubMed ID: 18211009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How similar are P450s and what can their differences teach us?
    Graham SE; Peterson JA
    Arch Biochem Biophys; 1999 Sep; 369(1):24-9. PubMed ID: 10462437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions of mammalian cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b(5) enzymes.
    Shimada T; Mernaugh RL; Guengerich FP
    Arch Biochem Biophys; 2005 Mar; 435(1):207-16. PubMed ID: 15680923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probing ligand binding modes of human cytochrome P450 2J2 by homology modeling, molecular dynamics simulation, and flexible molecular docking.
    Li W; Tang Y; Liu H; Cheng J; Zhu W; Jiang H
    Proteins; 2008 May; 71(2):938-49. PubMed ID: 18004755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome p450 in silico: an integrative modeling approach.
    de Graaf C; Vermeulen NP; Feenstra KA
    J Med Chem; 2005 Apr; 48(8):2725-55. PubMed ID: 15828810
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites.
    Ekins S; de Groot MJ; Jones JP
    Drug Metab Dispos; 2001 Jul; 29(7):936-44. PubMed ID: 11408357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetic deuterium isotope effects for 7-alkoxycoumarin O-dealkylation reactions catalyzed by human cytochromes P450 and in liver microsomes. Rate-limiting C-H bond breaking in cytochrome P450 1A2 substrate oxidation.
    Kim KH; Isin EM; Yun CH; Kim DH; Guengerich FP
    FEBS J; 2006 May; 273(10):2223-31. PubMed ID: 16649998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochromes P450 and drug discovery.
    Lamb DC; Waterman MR; Kelly SL; Guengerich FP
    Curr Opin Biotechnol; 2007 Dec; 18(6):504-12. PubMed ID: 18006294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome p450 conformational diversity.
    Stout CD
    Structure; 2004 Nov; 12(11):1921-2. PubMed ID: 15530355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of chronic exposure to cadmium on renal cytochrome P450-dependent monooxygenase system in rats.
    Plewka A; Plewka D; Nowaczyk G; Brzóska MM; Kamiński M; Moniuszko-Jakoniuk J
    Arch Toxicol; 2004 Apr; 78(4):194-200. PubMed ID: 14595535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of binding modes for ligands in the cytochromes P450 and other heme-containing proteins.
    Kirton SB; Murray CW; Verdonk ML; Taylor RD
    Proteins; 2005 Mar; 58(4):836-44. PubMed ID: 15651036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystal structure of CYP199A2, a para-substituted benzoic acid oxidizing cytochrome P450 from Rhodopseudomonas palustris.
    Bell SG; Xu F; Forward I; Bartlam M; Rao Z; Wong LL
    J Mol Biol; 2008 Nov; 383(3):561-74. PubMed ID: 18762195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compound lipophilicity for substrate binding to human P450s in drug metabolism.
    Lewis DF; Jacobs MN; Dickins M
    Drug Discov Today; 2004 Jun; 9(12):530-7. PubMed ID: 15183161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling and synthesis of novel tight-binding inhibitors of cytochrome P450 2C9.
    Peng CC; Rushmore T; Crouch GJ; Jones JP
    Bioorg Med Chem; 2008 Apr; 16(7):4064-74. PubMed ID: 18255300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Class-dependent sequence alignment strategy improves the structural and functional modeling of P450s.
    Baudry J; Rupasinghe S; Schuler MA
    Protein Eng Des Sel; 2006 Aug; 19(8):345-53. PubMed ID: 16777908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.